DNTH (Dianthus Therapeutics) Short Percentage of Float


DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $94.34
GF Value $2.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

DNTH vs CAI, TNGX, MANE: Short Percentage of Float Comparison

For the Biotechnology subindustry, Dianthus Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dianthus Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Short Percentage of Float falls into.


DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $94.34 is trading 3141.9% above its estimated GF Value™ of $2.91. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Short Percentage of Float:
  • GF Value™: $2.91 vs. price of $94.34 (3141.9% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$94.34
Price
$2.91
GF Value